太平洋证券此前指出，公司在手现金充沛，期间费用保持平稳。2023年公司共收到拜耳2笔里程碑付款，合计12亿元。毛利方面，2023年华堂宁毛利率为48.8%（同比+5.1pct），预计2024年将继续稳步提升。Hualing Medicine-B (02552) rose more than 4%, as of the press release, rose 4.43%, reported HKD 1.65, turnover of HKD 1.684 million.
According to the Zhitong Finance APP, Hualing Medicine-B (02552) rose more than 4%, as of the press release, rose 4.43%, reported HKD 1.65, turnover of HKD 1.684 million.
On the news side, Hualing Medicine announced that its wholly-owned subsidiary, Shengderui of the Company, will showcase a number of latest research results in the form of posters at the 84th annual American Diabetes Association (ADA) Scientific Meeting. These latest research results show that Hualing Medicine is continuously deepening and expanding its research on glucokinase, as well as actively conducting research on new targets and drug mechanisms, in order to explore more disease areas and new drug development pipelines. It is reported that this year's ADA Annual Meeting will be held in Orlando, USA from June 21-24, 2024.
On the cash front, Pacific Securities previously pointed out that the company has sufficient cash on hand and stable expenses. In 2023, the company received two milestone payments from Bayer, totaling RMB 1.2 billion. As for gross margin, in 2023, Huatengning's gross margin was 48.8% (up 5.1pct year-on-year), and it is expected to continue to steadily increase in 2024.
